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Abstract
Background: Tyrosinemia type 1 is an autosomal recessive disorder of amino acid metabolism. Without treatment,
death in childhood is common. Treatment with nitisinone and dietary restrictions are associated with improved
outcomes; some studies suggest better outcomes when treatment begins at an asymptomatic stage. Newborn
screening allows for earlier identification, but there is uncertainty regarding the test accuracy of the current method:
succinylacetone measurement in dried blood spots using tandem mass spectrometry.
Methods: We conducted a systematic review of literature published up to January 2016. Two reviewers independently
assessed titles, abstracts, full texts, and conducted quality appraisals. A single reviewer extracted data, which
was checked by a second reviewer.
Results: Ten studies provided test accuracy data: five studies reporting screening experiences and five case–control
studies. Sensitivity (29 cases in total) and specificity (34,403 controls in total) were 100% in the case–control studies, but
could not be calculated in the studies reporting screening experiences due to a lack of follow-up of screen-negative
babies. Positive predictive values in the screening experience studies ranged from 66.7% (2 true positive cases, 1 false
positive case from ~500,000 people screened) to 100% (8 true positive cases from 856,671 people screened); negative
predictive values could not be calculated. Positive and negative predictive values cannot be calculated from
case–control studies.
Conclusions: Screening for Tyrosinemia type 1 using tandem mass spectrometry measurement of succinylacetone
from dried blood spots appears to be promising. Confirmation of test accuracy data should be obtained from studies
that include a two-year follow-up of individuals who screen negative.
Keywords: Systematic review, Tyrosinemia, Test accuracy, Succinylacetone, Inborn errors of metabolism, Newborn
blood spot screening, Tandem mass spectrometry
Background
Tyrosinemia type 1 (TYR1), also known as fumarylace-
toacetase deficiency (Enzyme Commission Number
3.7.1.2), is an autosomal recessive disorder of amino acid
metabolism. It is caused by a deficiency in the activity of
fumarylacetoacetic hydrolase, the final enzyme in the
tyrosine degradation pathway, which leads to a toxic
build-up of fumarylacetoacetate, maleylacetoacetate, and
succinylacetone (SUAC) [1]. TYR1 is characterised by
progressive liver, kidney, and neurological disease [2].
Acute (presenting before six months of age), sub-acute
(presenting between six and 12 months) and chronic
(presenting after one year) forms of the disease have
been described [2]. Without treatment, the prognosis for
individuals with TYR1 is poor, with high levels of death
during childhood due to liver failure, recurrent bleeding,
hepatocellular carcinoma, and porphyria-like syndrome
with respiratory failure [3]. However, treatment with
nitisinone and dietary restrictions are associated with
reductions in morbidity and mortality [4–6]; liver trans-
plantation is indicated if these treatment fail or if
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hepatocellular carcinoma develops [2]. The incidence of
TYR1 is estimated to be approximately 1:100,000 live
births, but reported values range from 1:1,846 [7] to
1:781,144 live births [8]. The incidence of TYR1 is
higher in Quebec, Canada, possibly due to a founder ef-
fect for Tyrosinemia and high gene frequency [7], and in
Asian children in the West Midlands of the UK [9], and
in North Africa and the Middle East [10], possibly due
to parental consanguinity [9].
Screening for TYR1 amongst newborn babies is con-
ducted in many countries around the world. While tyro-
sine levels have been used as the primary screening
marker for TYR1, it is not consistently raised in individ-
uals who have TYR1 [11], and it can be elevated in indi-
viduals with other conditions and in unaffected babies
[12, 13]. In 2004, Allard and colleagues developed an
alternative method to screen for TYR1 using tandem
mass spectrometry (MS/MS) to determine SUAC in
dried blood spots (DBS) [14]. A rapid review of literature
published up to 2012 reported that “Screening pro-
grammes using succinylacetone as a marker have re-
ported 100% sensitivity and 100% specificity. However,
other studies have reported the identification of false
positives.” [15]. The aim of the current review was to
examine the range of test accuracy indicators (sensitivity,
specificity, and predictive values) of succinylacetone
measurement in DBS using MS/MS for TYR1 screening
using full systematic review methods.
Methods
Search strategy
We conducted searches in the following electronic data-
bases: Medline, Medline In-Process & Other Non-
Indexed Citations, Embase, Web of Science (All Data-
bases), and the Cochrane Library. We searched using
text word and MeSH terms relating to “Tyrosinemia
type 1 OR inborn errors of metabolism”, AND “succiny-
lacetone OR DBS OR (tandem mass spectrometry AND
neonatal screening)”. Full details of the search strategy
are provided in Additional file 1: supplement 1. The
search was conducted on 26th January 2016. We exam-
ined reference lists of included studies and previous
reviews. Experts in the field and organisations were
contacted for studies not in the public domain.
Eligibility criteria
We included English language journal articles which in-
vestigated screening for TYR1 by MS/MS analysis of
SUAC from DBS in newborns. The reference standard
was urine testing for SUAC, clinical detection of TYR1 or
two-year follow-up. Outcomes included were any reported
test accuracy measures from cross-sectional studies, case–
control studies, or studies reporting screening experiences.
We excluded non-human studies, papers not available in
English, letters, editorials, communications, grey litera-
ture, conference abstracts, and studies published before
2004 (the year the first paper was published on SUAC
measurement in DBS using MS/MS for TYR1) from
our review.
Screening and data extraction
Screening of titles and abstracts of all retrieved records, and
subsequently of full texts, was undertaken independently by
two reviewers. Data extraction was performed by a single re-
viewer, with all data extraction forms checked by a second
reviewer. Disagreements were resolved by discussion be-
tween the two reviewers or further discussion with a third
reviewer, leading to a consensus on inclusion/exclusion.
Quality appraisal
Quality of included studies was assessed independently
by two reviewers using the Quality Assessment Tool for
Diagnostic Accuracy Studies 2 [QUADAS-2; [16]] which
was tailored to the research as recommended. Tailoring
of the QUADAS-2 tool included adding a topic-specific
signalling question and defining appropriate reference
standards and cut-offs for participant exclusions, as well
as guidance on how many positive signalling questions
are required for an overall positive rating in terms of
bias and applicability concerns. (See Additional file 1:
supplement 2 for signalling questions and Additional
file 1: supplement 3 for guidance notes). Disagree-
ments were resolved by discussion between the two
reviewers or through discussion with a third reviewer,
leading to a consensus on study quality.
Data summary and synthesis
Meta-analysis was not possible due to incomplete 2x2
tables and heterogeneity in study design. Therefore, a
narrative synthesis of results is provided.
Results
Searching, sifting, and sorting
One thousand two hundred and seventy-five unique
records were identified. Seventy six were retained after
sifting titles and abstracts. Assessment of full text pa-
pers against inclusion/exclusion criteria resulted in ten
studies being included in our review; five studies
reporting screening experiences [12, 17–20] and five
retrospective case–control studies using stored samples
from known TYR1 cases [14, 21–24]. All ten papers
were identified through electronic database searches.
Full details regarding the numbers of studies retained
and excluded at each stage of the review is provided in
Fig. 1. A list of excluded studies (with reasons) is given
in Additional file 1: supplement 4.
Stinton et al. Orphanet Journal of Rare Diseases  (2017) 12:48 Page 2 of 8
Quality appraisal
The overall risk of bias and applicability concerns of the
included studies are provided in Fig. 2. A summary of
the methodological quality for each of the included
studies is given in Additional file 1: supplement 5. Risk
of bias was considered high in two or more domains in
six of ten studies (60%) and in one domain in the
remaining four studies (40%). No study was judged as
low or unclear risk of bias in all four domains. In the
patient selection domain, all five case–control studies
Full text articles included
N = 10
Full text articles assessed for 
eligibility
N = 76
Full text articles excluded
N = 66*


























Fig. 1 PRISMA flow diagram of records through the systematic review. *See Additional file 1: supplement 4 for list of excluded studies with reasons
Fig. 2 Risk of bias and applicability concerns graph: review authors’ judgements about each domain presented as percentages across included studies
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[14, 21–24] were considered to be at a high risk of bias.
One study reporting a screening experience [20] was
considered to be at a high risk of bias as the study popu-
lation included screening samples taken from babies that
were symptomatic and/or outside the ‘newborn’ period.
There were significant concerns regarding applicability
of the research to the UK screening population in seven
studies as the incidence of TYR1 was higher than
expected in the UK population and/or screened dried
blood spot samples were collected before five days or
after eight days of life [14, 17–20, 22, 24].
In the index test domain, five studies were judged to
have a high risk of bias as the results of the reference
test were known when interpreting the index test in all
case–control studies and the SUAC threshold was not
pre-specified [14, 21–24]. Applicability concerns were
low for all ten studies.
In the reference test domain, two studies were judged
to be at high risk of bias as case-controls received a
screening test (second-tier test measuring SUAC directly
or indirectly in babies with elevated tyrosine levels) as a
reference standard [23, 24]. The remainder of the studies
had an unclear risk of bias as they did not report the
method of diagnosis, or did not report sufficient infor-
mation to allow a judgement to be made [12, 14, 17–22].
Applicability concerns were high in seven studies as
babies that screened negative in studies reporting
screening experiences or were used as controls did
not receive an appropriate reference standard, i.e.
diagnostic testing or clinical follow-up for at least two
years [12, 17–20, 23, 24].
In the flow and timing domain, all ten studies were
considered to be at high risk of bias. The reasons for this
were that the reference standards used to confirm TYR1
status for screen-positives and screen negatives (or cases
and controls) were not the same, follow-up of those
people who screened-negative was not defined or not
conducted, and losses to follow-up were not reported
[12, 14, 17–24].
Characteristics of included studies
Included studies are summarised in table 1 and Add-
itional file 1: supplement 6. There were ten studies. Five
studies reported experiences of newborn screening pro-
grammes [12, 17–20]. Data were given for screening
periods ranging from 16 weeks [19] to four years one
month [20]; the number of analysed screening samples
ranged from 61,344, which included two cases [19], to
518,687, which included three cases [20]. Five papers re-
ported on case–control studies [14, 21–24] conducted
over periods between one [21] and five [22] months;
the number of screening samples ranged from ~1000,
which included six cases [21], to 13,532, which in-
cluded 11 cases [24].
Description of screening and diagnostic tests
Details of the MS/MS screening methodology and
diagnostic confirmation used in the included studies
are provided in Additional file 1: supplement 6. In
brief, two studies used commercially available MS/
MS assays [18, 23] while all others used non-kit
methods with derivatisation of SUAC to its hydra-
zine [12, 14, 17, 19–22, 24]. MS/MS analysis of
SUAC-hydrazone [12, 14, 19, 20, 24] or SUAC-hydrazone
butyl ester [17, 21–23] was performed; the MS/MS meth-
odology used was not reported by Lund et al. [18]. The
SUAC cut-off values used in the 10 studies ranged from
1.29 μmol/l [23] to 10 μmol/l [19]. No two studies used
the same cut-off value.
A range of approaches were reported for defining the
reference standard. For individuals who screened posi-
tive or were used as cases these were: clinical diagnosis
[14], “pre-natal testing” [12], DNA analysis [17, 18], ana-
lysis of SUAC in urine [12, 18, 19], analysis of plasma
amino acids [12, 18], “diagnostically confirmed in ac-
cordance with institutional guidelines” [23], and on the
basis of “symptoms consistent with TYR1” [20]. The
method of diagnosis was not reported by Dhillon and
colleagues [21] and la Marca and colleagues [22].
Four studies used more than one diagnostic approach
[12, 18–20]. For individuals who screened negative,
no clinical follow-up or other reference standard was
reported for all five experience reports [12, 17–20]. In
the five case–control studies, two conducted second-
tier testing (SUAC or 5-aminolevulinic acid dehydra-
tase [ALAD]) in DBS with elevated tyrosine levels to
identify healthy controls [23, 24], while the reference
standard to confirm absence of TYR1 was unclear in
the other three studies [14, 21, 22].
Accuracy of screening tests
The methods and thresholds used for screening, and
diagnostic tests varied between studies. Results were
considered positive when they exceeded the threshold as
set in the individual study. Table 1 shows the test accur-
acy data on sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV).
Sensitivity and specificity
It was not possible to calculate sensitivity and specificity
for the studies reporting screening experiences due to a
lack of follow-up of people who had screened negative.
For the case–control studies, sensitivity was estimated to
be 100% in each of the five studies, which included 29
cases in total [14, 17, 21, 23, 24]. Specificity was esti-
mated to be 100% in four studies [14, 22–24]. This
included 34,403 unaffected babies in total, 18,204 of
which had an inadequate reference standard. Specifi-
city could not be calculated for the study by Dhillon
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et al. [21] as they did not give a precise figure for the
number of controls.
Positive and negative predictive value
In the studies reporting screening experiences, the PPV
was 100% in four studies, with in total eight true positive
cases and no false positive cases out of 856,671 people
screened [17–20], and 66.7% in one study, with two true
positive cases and one false positive case out of
~500,000 babies screened [12]. There were very wide
confidence intervals due to the small number of cases.
NPV could not be calculated due to a lack of follow-up
of people who had screened negative. PPV and NPV
could not be calculated from the case–control studies as
these values are dependent on the prevalence of the dis-
ease in the population that is being tested.
Discussion
We examined the test accuracy of SUAC measurement
in DBS using MS/MS to screen for TYR1 in newborns.
Ten studies were identified which reported test accuracy
data; five studies reporting screening experiences and
five case–control studies. PPV in the studies reporting
screening experiences ranged from 67% (two true posi-
tive cases and one false positive case out of ~500,000
babies screened) to 100% (eight true positive cases and
no false positive cases out of 856,671 people screened).
We were unable to calculate sensitivity, specificity, or
negative predictive value in these studies due to a lack of
follow-up of babies who screened negative. Case–control
studies reported clear discrimination between SUAC
levels of newborns with and without TYR1.
No consistent test accuracy metric was available. Papers
reporting screening experiences suggested that using
SUAC to screen for TYR1 resulted in no false negative re-
sults, and reported test sensitivity and specificity of up to
100%. However, these conclusions were based on a lack of
awareness of false negative results rather than following
up babies who had screened negative. Without proper
follow-up of the population who have been tested, for an
appropriate amount of time, it is not possible to know if
the absence of awareness of false negatives reflects an ac-
tual absence of false negative results.
While case–control studies showed no overlap in
SUAC levels between newborns with and without TYR1,
the cut-offs used varied between studies and were speci-
fied retrospectively, and the assessors were not blinded
to the disease status, which can result in overestimation
of test accuracy. The included case–control studies were
also at high or unclear risk of differential verification
bias as TYR1 cases and healthy controls received differ-
ent reference standards, the reference standards used
were not reported in sufficient detail to assess if their ac-
curacy was comparable, or they were not reported at all.
The use of multiple reference standards across partici-
pants of a single study might have resulted in an over-
estimation of accuracies [25]. In addition, studies
evaluating diagnostic tests in a diseased population and
a separate healthy control group can overestimate the
diagnostic performance compared with studies that use
the index test in a clinical population covering the full
range of patients without knowing their disease
status [25].
Our understanding of the appropriateness of screening
for TYR1 using SUAC is limited by heterogeneity in
study design, the methods used for SUAC determination
on DBS, and the SUAC cut-off values. For example, the
SUAC cut-offs used in the screening test to identify pos-
sible cases of TYR1 ranged from 1.29 μmol/l [23] to
10 μmol/l [19]. Proficiency testing results for SUAC in
dried blood spots have shown large differences among
screening laboratories in SUAC recovery reflecting ana-
lytic biases, which might explain the wide variation in
cut-off values of the studies in our review [26]. Differ-
ences in recovery could be explained by the method
used (kit TMS vs. non-kit TMS; butyl ester derivatisa-
tion vs. non-derivatisation), DBS extraction strategy
(freshly punched DBS, residual DBS or co-extraction of
AA, AC, and SUAC, respectively), internal standard used
(13C-SUAC, 5,7-dioxooctanoic acid, or TMS kit internal
standard), or the calibration strategy used (DBS calibra-
tors, TMS internal standard/other liquid standard or kit
internal standard only, respectively). Laboratories that
measure low quantitative SUAC results usually used
lower cut-off values to avoid misclassifications [26]. This
highlights an important issue in how screening tests are
evaluated. In this paper, we examine test accuracy,
meaning the association between results from the test
under investigation with the presence or absence of the
target disease. However, the term ‘accuracy’ has multiple
meanings. Within method validation (the process used
to confirm that tests are suitable for their intended pur-
pose), ‘analytical’ accuracy refers to the degree to which
test results and the true value of the measured quantity
agree and how reproducible and reliable the test is [27].
The analytical performance of the used SUAC assays has
been described in some of the included studies. The re-
covery of SUAC was assessed in five studies by assaying
DBS specimens enriched with predetermined (low to
high) SUAC concentrations and was reported to be 51%
[23], 72-80% [19], 75-78% [14], 75-86% [21], and 97-
100% [22] of the expected value, respectively. The quan-
tification limit (the lowest amount of SUAC in a sample
which can be reliably quantified) was reported in four
studies and was 0.4 μmol/l [22], 0.5 μmol/l [19, 23] and
1 μmol/l [14]. The calibration was reported to be linear
up to 50 μmol/l [14], 100 μmol/l [19, 22, 24], 240 μmol/l
[21], and 250 μmol/l [23], respectively. Precision (the
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ability to consistently reproduce a result when sub-
samples are taken from the same specimen) results were
presented in seven studies with inter-assay coefficients
of variation (CV) at different SUAC concentrations of
10.0-12.2% [14], 7.1-8.5% [21], 3.50-4.49% [22], 5.8-13%
[19], 15.8-16.7% [24], 17.29-19.00% [23] and 30% in a
pooled sample assay [20]. Taken together, the analytical
performance of the screening tests used in the
included studies was in agreement with previously
reported proficiency testing outcomes [26, 28, 29],
showing large between-laboratory differences in SUAC
recoveries (mostly incomplete recoveries) depending
on the method used and reproducible within-laboratory
recoveries. There is need to harmonise quantitative results
among laboratories. Despite differences among methods
in SUAC recoveries (analytical bias), each method seems
to have an acceptable precision and might therefore still
be able (when using a cutoff value appropriate for the se-
lected method) to reliably sort asymptomatic newborns
into probable TYR1 cases and non-cases. De Jesus et al.
[29] and Adam et al. [26] stress in their papers that bias in
quantitative results can be tolerated if the screening test
reliably sorts people into those who (probably) do have
the disease of interest and those who (probably) don’t.
Any differences in the test accuracy between studies might
be due to the timing of the test, the SUAC assay used, the
cut-off used for classifying the disease status, use of repeat
testing in samples with borderline SUAC levels, or
variation in normal SUAC values in the tested new-
born population.
Our review has a number of limitations. First, we were
unable to synthesise our findings numerically due to in-
complete 2x2 tables for reporting screening experiences,
and heterogeneity in study design, the MS/MS method
used, and the SUAC cut-off values. Second, we restricted
our search to English language papers; non-English-
language papers may be available and add further infor-
mation. Third, we tailored the applicability questions for
the QUADAS-2 in relation to the newborn screening in
the UK. For example, in the UK newborn screening
takes place five to eight days after birth, so studies in
which samples were taken before or after this were rated
as having high concerns regarding applicability. None of
the studies we identified were conducted in the UK, and
the usual time at which screening takes place varies by
country; in many European countries newborn screening
is conducted three days after birth. Therefore, the cri-
teria for a high applicability concern might be different
outside the UK.
While results from case–control studies are promising
they are not definitive, as we know that case–control de-
signs tend to overestimate test accuracy [25]. A research
project using MS/MS measurement of SUAC from DBS
with follow-up of screen-negatives for at least two years
would considerably strengthen the test accuracy data.
This could be achieved by following up one of the existing
cohorts described in this review by searching hospital/pri-
mary care databases for cases of TYR1 that were identified
symptomatically. While this approach would not provide
a definitive answer, it would enable a measure of false-
negative cases that is currently missing from the literature.
Conclusions
MS/MS measurement of SUAC from DBS looks like a
promising screening test for TYR1 but test accuracy
from proof-of-concept studies should be confirmed in
screening studies that include appropriate follow-up of
screen-negatives.
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